自身免疫性神经肌肉接头疾病的流行病学、诊断与生物标志物
本文综述自身免疫性神经肌肉接头疾病的流行病学、诊断方法和生物标志物。全球研究提示乙酰胆碱受体抗体阳性重症肌无力年发病率可达每百万人29例,肌肉特异性酪氨酸激酶抗体阳性重症肌无力和Lambert-Eaton肌无力综合征约少见20倍。诊断方法包括血清学抗体、电生理、影像和药理学试验,但临床或试验中预测病程的客观生物标志物仍需探索。
要点
- 50岁以上人群重症肌无力识别增加,乙酰胆碱受体抗体阳性年发病率可达每百万人29例。
- 肌肉特异性酪氨酸激酶抗体阳性重症肌无力和Lambert-Eaton肌无力综合征约少见20倍。
- 诊断方法包括血清学抗体、电生理、影像和药理学试验,临床或试验用客观生物标志物仍需探索。
核心结论
- 尽管已有明确的诊断参数将患者分为亚组,但临床或临床试验中用于预测重症肌无力和Lambert-Eaton肌无力综合征病程的客观生物标志物仍需探索。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 过去5-10年全球流行病学研究提示乙酰胆碱受体抗体阳性重症肌无力年发病率可达每百万人29例。
- 肌肉特异性酪氨酸激酶抗体阳性重症肌无力和Lambert-Eaton肌无力综合征约少见20倍。
- 重症肌无力可与胸腺瘤相关,Lambert-Eaton肌无力综合征与小细胞肺癌相关,判断是否为副肿瘤性对预后很重要。
- 疾病病程可用国际公认的临床评分或患者报告结局指标随访。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune neuromuscular junction disorders are rare. However, myasthenia gravis is being increasingly recognised in people older than 50 years. In the past 5-10 years, epidemiological studies worldwide suggest an incidence of acetylcholine receptor antibody-positive myasthenia gravis of up to 29 cases per 1 million people per year. Muscle-specific tyrosine kinase antibody-positive myasthenia gravis and Lambert-Eaton myasthenic syndrome are about 20 times less common. Several diagnostic methods are available for autoimmune neuromuscular junction disorders, including serological antibody, electrophysiological, imaging, and pharmacological tests. The course of disease can be followed up with internationally accepted clinical scores or patient-reported outcome measures. For prognostic purposes, determining whether the disease is paraneoplastic is of great importance, as myasthenia gravis can be associated with thymoma and Lambert-Eaton myasthenic syndrome with small-cell lung cancer. However, despite well defined diagnostic parameters to classify patients into subgroups, objective biomarkers for use in the clinic or in clinical trials to predict the course of myasthenia gravis and Lambert-Eaton myasthenic syndrome are needed.
引用
- Punga AR, Maddison P, Heckmann JM, et al. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022. PMID: 35065040. doi:10.1016/S1474-4422(21)00297-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。